Overview

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

Status:
Active, not recruiting
Trial end date:
2022-01-22
Target enrollment:
Participant gender:
Summary
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Inc.